Published in AIDS Weekly, April 9th, 2001
Testing of the vaccine will begin later in Kenya.
The MVA, or modified vaccinia Ankara, vaccine is the first of its kind to be tested in humans. Derived from a virus used in smallpox immunization, the vaccine aims to stimulate the production of a certain kind of immune cell that kills other cells infected with HIV. The vaccine is attenuated through genetic modification so it cannot cause infection with either HIV or pox...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.